This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEJ5B0DE_L.jpg
The company will also amend its annual filing for 2022 to reflect a $26 million deduction caused by a revenue recognition error.
Catalent had delayed its quarterly results report thrice in less than a month, pending the adjustments needed on historical financial statements related to its Bloomington operations.
Shares of the company rose 3% to $40 in premarket trading.
In May, Catalent said production snags at three of its facilities – Maryland, Indiana and Brussels – had driven up costs and also contributed to the delay in reporting results. Its cost-cutting plans have also been hampered by regulatory inspections and subsequent corrective actions.
The company then changed the financial directors at its locations facing the biggest challenges, and named a new interim CFO in April.
Catalent is yet to provide details of what was behind the production issues.
The contract drug manufacturer now expects full-year revenue in the range of $4.23 billion to $4.33 billion, from a prior forecast of $4.25 billion to $4.35 billion. Analysts on average were expecting $4.3 billion, according to Refinitiv.
Excluding items, it reported a third-quarter loss of $17 million, or 9 cents per share, compared with an adjusted profit of $188 million, or $1.04 per share, a year ago. Analysts on average had expected a loss of 3 cents.
